Tags

Type your tag names separated by a space and hit enter

Therapeutic novelties in migraine: new drugs, new hope?
J Headache Pain. 2019 Apr 17; 20(1):37.JH

Abstract

BACKGROUND

In the past decade, migraine research has identified novel drug targets. In this review, we discuss recent data on emerging anti-migraine therapies.

MAIN BODY

The development of ditans, gepants and anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of migraine is one of the greatest advances in the migraine field. Lasmiditan, rimegepant and ubrogepant will extend our therapeutic armamentarium for managing acute migraine attacks when triptans are not effective or contraindicated due to cardiovascular disorders. The monoclonal antibodies are migraine specific prophylactic drugs with high responder rates and favorable adverse event profiles. Furthermore, they offer convenient treatment regimens of 4- or 12-week intervals.

CONCLUSION

Collectively, novel migraine therapies represent a major progress in migraine treatment and will undoubtedly transform headache medicine.

Links

PMC Free PDF

Authors+Show Affiliations

Do TP
Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Guo S
Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Ashina M
Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. ashina@dadlnet.dk.

MeSH

AnalgesicsAnimalsCalcitonin Gene-Related Peptide Receptor AntagonistsHumansMigraine DisordersPyridinesPyrrolesRandomized Controlled Trials as TopicTryptamines

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30995909

Citation

Do, Thien Phu, et al. "Therapeutic Novelties in Migraine: New Drugs, New Hope?" The Journal of Headache and Pain, vol. 20, no. 1, 2019, p. 37.
Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019;20(1):37.
Do, T. P., Guo, S., & Ashina, M. (2019). Therapeutic novelties in migraine: new drugs, new hope? The Journal of Headache and Pain, 20(1), 37. https://doi.org/10.1186/s10194-019-0974-3
Do TP, Guo S, Ashina M. Therapeutic Novelties in Migraine: New Drugs, New Hope. J Headache Pain. 2019 Apr 17;20(1):37. PubMed PMID: 30995909.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapeutic novelties in migraine: new drugs, new hope? AU - Do,Thien Phu, AU - Guo,Song, AU - Ashina,Messoud, Y1 - 2019/04/17/ PY - 2018/12/26/received PY - 2019/02/18/accepted PY - 2019/4/19/entrez PY - 2019/4/19/pubmed PY - 2019/7/19/medline KW - Adverse event KW - Antibody KW - Ditan KW - Efficacy KW - Gepant KW - Migraine KW - Randomized clinical trial KW - Tolerability SP - 37 EP - 37 JF - The journal of headache and pain JO - J Headache Pain VL - 20 IS - 1 N2 - BACKGROUND: In the past decade, migraine research has identified novel drug targets. In this review, we discuss recent data on emerging anti-migraine therapies. MAIN BODY: The development of ditans, gepants and anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of migraine is one of the greatest advances in the migraine field. Lasmiditan, rimegepant and ubrogepant will extend our therapeutic armamentarium for managing acute migraine attacks when triptans are not effective or contraindicated due to cardiovascular disorders. The monoclonal antibodies are migraine specific prophylactic drugs with high responder rates and favorable adverse event profiles. Furthermore, they offer convenient treatment regimens of 4- or 12-week intervals. CONCLUSION: Collectively, novel migraine therapies represent a major progress in migraine treatment and will undoubtedly transform headache medicine. SN - 1129-2377 UR - https://www.unboundmedicine.com/medline/citation/30995909/Therapeutic_novelties_in_migraine:_new_drugs_new_hope DB - PRIME DP - Unbound Medicine ER -